Colorectal Cancer Metastatic

Oncology
17
Pipeline Programs
9
Companies
11
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
5
1
5
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Small Molecule
133%
+ 12 programs with unclassified modality

On Market (4)

Approved therapies currently available

U
CAPECITABINEApproved
capecitabine
Unknown Company
oral2017
Regeneron
EYLEAApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2011
Regeneron
EYLEA HDApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2023
U
XELODAApproved
capecitabine
Unknown Company
Nucleoside Metabolic Inhibitor [EPC]oral1998

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
5 programs
2
3
1
AFLIBERCEPTPhase 3
AFLIBERCEPT AVE0005Phase 3
AfliberceptPhase 3
AfliberceptPhase 2
CapecitabinePhase 21 trial
Active Trials
NCT05064085Active Not Recruiting13Est. Sep 2026
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
FOLFIRI+cetuximabPhase 3Monoclonal Antibody1 trial
EDP1503Phase 11 trial
Active Trials
NCT03775850Completed69Est. Oct 2021
NCT07004413Not Yet Recruiting267Est. Jan 2031
Roche
RocheSTAVANGER NORWAY, Norway
2 programs
1
1
CapecitabinePhase 31 trial
PolyPEPI1018Phase 21 trial
Active Trials
NCT05243862Active Not Recruiting18Est. Jun 2026
NCT01249638Unknown516Est. Dec 2016
AS
AB ScienceFrance - Paris
1 program
1
MasitinibPhase 2/3Small Molecule1 trial
Active Trials
NCT03556956CompletedEst. Dec 2020
Varian Medical Systems
1 program
1
Local consolidative therapyPhase 21 trial
Active Trials
NCT05062720WithdrawnEst. Oct 2025
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
PanitumumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03751176Unknown31Est. Nov 2022
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
Aldoxorubicin HydrochloridePhase 1/21 trial
Active Trials
NCT03563157Terminated2Est. Aug 2019
Verona Pharma
Verona PharmaUK - London
1 program
Major liver resectionN/A1 trial
Active Trials
NCT05475041CompletedEst. Jul 2022
Taiho Oncology
Taiho OncologyNJ - Princeton
1 program
TAS-102N/A1 trial
Active Trials
NCT02286492Approved For Marketing

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.FOLFIRI+cetuximab
RocheCapecitabine
AB ScienceMasitinib
RochePolyPEPI1018
Varian Medical SystemsLocal consolidative therapy
AmgenPanitumumab
ImmunityBioAldoxorubicin Hydrochloride
RegeneronCapecitabine
Merck & Co.EDP1503
Verona PharmaMajor liver resection

Clinical Trials (11)

Total enrollment: 916 patients across 11 trials

NCT07004413Merck & Co.FOLFIRI+cetuximab

Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

Start: Jan 2026Est. completion: Jan 2031267 patients
Phase 3Not Yet Recruiting
NCT01249638RocheCapecitabine

Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

Start: Dec 2010Est. completion: Dec 2016516 patients
Phase 3Unknown
NCT03556956AB ScienceMasitinib

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Start: Jul 2015Est. completion: Dec 2020
Phase 2/3Completed
NCT05243862RochePolyPEPI1018

Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

Start: Jun 2022Est. completion: Jun 202618 patients
Phase 2Active Not Recruiting
NCT05062720Varian Medical SystemsLocal consolidative therapy

Local Consolidative Therapy in Colorectal Cancer

Start: Jul 2021Est. completion: Oct 2025
Phase 2Withdrawn
NCT03751176AmgenPanitumumab

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

Start: Nov 2018Est. completion: Nov 202231 patients
Phase 2Unknown
NCT03563157ImmunityBioAldoxorubicin Hydrochloride

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Start: Sep 2018Est. completion: Aug 20192 patients
Phase 1/2Terminated
NCT05064085RegeneronCapecitabine

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Start: Oct 2021Est. completion: Sep 202613 patients
Phase 1Active Not Recruiting
NCT03775850Merck & Co.EDP1503

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Start: Dec 2018Est. completion: Oct 202169 patients
Phase 1Completed
NCT02286492Taiho OncologyTAS-102

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

N/AApproved For Marketing
NCT05475041Verona PharmaMajor liver resection

Perioperative Outcomes of Simultaneous Colorectal and Liver Resections

Start: Jun 2022Est. completion: Jul 2022
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3m ago

Office Administrator

SystImmune
3m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
17m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
17m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)